LSLiora Michal Schultz

Liora Michal Schultz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liora Michal Schultz has a total of 263 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Venetoclax as Salvage Treatment for Relapsed/Refractory B‐ALL Post‐CAR‐T Therapy

    by Elizabeth E. Dong, Deborah Schiff, Jenna Rossoff, Alex Hoover, Holly Pacenta, Elliot Stieglitz, Jodi Skiles, Christine L. Phillips, Erin Guest, Jonathan D. Bender, et al.

    Background: Despite high early response rates following chimeric antigen receptor T‐cell therapy (CAR‐T) for relapsed/refractory pediatric B‐cell acute lymphoblastic leukemia (B‐ALL), many patients relapse, and downregulation of the antigen targeted by the CAR‐T has emerged as a major challenge. Furthermore, minimal residual disease (MRD) screening using next‐generation sequencing (NGS) does not inform antigen status. In cases of either antigen downregulation or unknown antigen status, there is a need for antigen‐agnostic salvage agents such as venetoclax. Data regarding venetoclax use in the post‐CAR‐T setting, however, remain limited. Procedure: We conducted a retrospective study of patients with B‐ALL who received CAR‐T therapy followed by venetoclax from nine tertiary pediatric oncology centers in the United States. Results: Nineteen patients received venetoclax for treatment of relapsed/refractory (R/R) B‐ALL following CAR‐T therapy. The median number of relapses pre‐venetoclax was 2 (range, 1–5). Of 12 patients with known antigen expression status at venetoclax initiation, 11 (92%) had antigen downregulation. Side effects of venetoclax monotherapy were nausea (100%) and rash (25%); in combination chemotherapy, cytopenias (63%) and infections (42%) were also reported. No patient deaths occurred from venetoclax toxicity. After venetoclax, 8 of 19 patients (42%) achieved either morphologic complete remission (CR) or clearance of prior MRD. Of 11 patients with baseline MRD‐only disease, 4 (36%) achieved MRD negativity. Of 8 patients with baseline morphologic disease, 2 (25%) achieved morphologic CR. Patients with antigen downregulation had a 29% morphologic CR rate. Conclusions: Our experience suggests tolerability and promise of venetoclax in pediatric R/R B‐ALL, including patients with antigen downregulation.

  • Peripheral blasts at apheresis as a risk factor for survival after tisagenlecleucel in children and young adults

    by Kaylyn Utley Lyons, Kristen R. Miller, Arpita Deb, Andrew Nicklawsky, Christina Baggott, Khanh Nguyen, Snehit Prabhu, Holly Pacenta, Christine L. Phillips, Jenna Rossoff, et al.

    Precursor B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood malignant neoplasm. Relapsed or refractory (R/R) B-ALL carries a dismal prognosis. CD19-specific chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment, yet relapse rates among responders remain high, with 40% to 50% experiencing relapse after therapy. This underscores the need for improved strategies to predict and prevent relapses after CAR T-cell therapy. This study reports the impact of peripheral blasts at the time of apheresis on outcomes in pediatric and young adult patients with R/R B-ALL treated with CD19-specific CAR T-cell therapy. A multi-institutional cohort of 162 patients from the Pediatric Real-World CAR Consortium was retrospectively analyzed. Key outcomes, such as day 28 response, event-free survival (EFS), and overall survival (OS), were evaluated based on the presence vs absence of peripheral blasts at apheresis. Although response at day 28 was comparable among peripheral blast groups in this cohort, the presence of peripheral blasts at apheresis was associated with inferior EFS (27% vs 55% at 12 months) and OS (55% vs 78% at 12 months). However, this association was confounded by disease burden at the time of infusion. In multivariable analysis, higher blast percentage at apheresis was not associated with an increased hazard of death (hazard ratio, 1.11; 95% confidence interval, 0.93-1.33; P = .25). These findings suggest that the association between peripheral blasts at apheresis and inferior survival is largely influenced by disease burden at infusion.

  • HLH-like syndromes associate with increased risk of death and CD19− relapse after CAR T in pediatric B-ALL

    by Kevin O. McNerney, Soyang Kwon, Swati Naik, Vanessa A. Fabrizio, Gabriela Llaurador Caraballo, L. Nelson Sanchez-Pinto, Aimee Talleur, Xiaopei Zeng, Christina Baggott, Anant Vatsayan, et al.

    We previously reported poor long-term outcomes in patients with B-acute lymphoblastic leukemia (B-ALL) who developed hemophagocytic lymphohistiocytosis (HLH)–like toxicities (HLH-LT) after treatment with tisagenlecleucel. Since then, a consensus definition, immune effector cell–associated HLH-like syndrome (IEC-HS), was developed. Here, we report results from a multicenter retrospective study of children and young adults with B-ALL treated with tisagenlecleucel between 2018 and 2023, describing the incidence, diagnostic overlap, clinical phenotypes, and associated long-term outcomes of HLH-like syndromes. Of 154 tisagenlecleucel recipients, 14.9% met IEC-HS criteria, 21.4% met HLH-LT criteria, and 13% were identified as having HLH by treating institutions in the electronic health record; 10% met all definitions. Each HLH-like syndrome was associated with shortened overall survival and event-free survival, adjusting for baseline disease burden (P< .0001). Those with any HLH-like syndrome experienced 1-year cumulative incidence of nonresponse/relapse of 60% (95% confidence interval [CI], 43.1-76.9) vs 28.2% (95% CI, 20.0-36.5), P< .001, and nonrelapse mortality of 11.4% (95% CI, 0.7-22.1) vs 0% (95% CI, 0-0), P< .001, compared with those without. In those with high disease burden, patients with any HLH-like syndrome had a 1-year cumulative incidence of CD19− relapse of 65.2% (95% CI, 44.7-85.8) vs 2% (95% CI, 0-6.4) in those with no HLH-like syndrome, P< .001. Furthermore, adjusting for disease burden, any HLH-like syndrome was independently predictive of CD19− relapse with a hazard ratio of 8.10 (95% CI, 3.6-18.4), P< .001. These findings demonstrate partial definitional overlap of HLH-like syndromes and the prognostic significance of IEC-HS and identify CD19− relapse and nonrelapse mortality as key outcome drivers.

  • Open Access

    Tracking B-cell depletion and reconstitution using next-generation immunosequencing

    by Lik Wee Lee, Rohaum Hamidi, Christina Baggott, Liora Schultz, Ilan Kirsch

  • Open Access

    Interpreting next-generation immunosequencing results in children and young adults with acute lymphoblastic leukemia

    by Rohaum Hamidi, Ilan Kirsch, Liora Schultz

    Determination of measurable residual disease (MRD) in pediatric acute lymphoblastic leukemia (ALL) using next-generation immunosequencing (clonoSEQ; Adaptive Biotechnologies) has emerged as an essential and sensitive tool. The clonoSEQ assay identifies and tracks all the B-cell and T-cell receptor rearrangements present in a sample. With widening clinical use of immunosequencing for MRD monitoring (next-generation sequencing [NGS]-MRD), clinicians are increasingly encountering cases with results that are considered to be inconclusive, where immunosequencing yields detectable clonotypic sequences, yet it is unclear whether they indicate ALL, normal background, or an independent etiology. There is a need for guidance in the clinical interpretation of immunosequencing results. In this article, we describe various features of immunosequencing reporting and their clinical implications through a series of illustrative clinical cases. Each case presents a distinct scenario encountered in the clinical setting where NGS-MRD had varying clinical implications. Through aggregate evaluation of the various components of the results, such as the sequence locus, sequence abundance, clonal tracking, and levels of detection and blank, we formulate systematic interpretative tools that can be leveraged to inform clinical decision-making. The goal of this article is to serve as a useful guide for clinicians as they interpret immunosequencing results for pediatric ALL.


  • Open Access

    Supplemental Figure 13 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome

    by Hrishikesh K. Srinagesh, Anne Marijn Kramer, John H. Baird, Agnes Reschke, Bita Sahaf, Juancarlos Cancilla, Shriya Syal, Yi-Jiun Su, Neha Agarwal, Alexandria M. Jensen, et al.

    Supplemental Figure 13 shows ROC curves for the two cytokine signature at D14 and D21

  • Open Access

    Supplemental Figure 1 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome

    by Hrishikesh K. Srinagesh, Anne Marijn Kramer, John H. Baird, Agnes Reschke, Bita Sahaf, Juancarlos Cancilla, Shriya Syal, Yi-Jiun Su, Neha Agarwal, Alexandria M. Jensen, et al.

    Supplemental Figure 1 shows individual lab values over time for grade 2+ IECHS

  • Open Access

    Supplemental Table 7 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome

    by Hrishikesh K. Srinagesh, Anne Marijn Kramer, John H. Baird, Agnes Reschke, Bita Sahaf, Juancarlos Cancilla, Shriya Syal, Yi-Jiun Su, Neha Agarwal, Alexandria M. Jensen, et al.

    Clinical manifestations of gr2+ CRS.

  • Open Access

    Supplemental Figure 5 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome

    by Hrishikesh K. Srinagesh, Anne Marijn Kramer, John H. Baird, Agnes Reschke, Bita Sahaf, Juancarlos Cancilla, Shriya Syal, Yi-Jiun Su, Neha Agarwal, Alexandria M. Jensen, et al.

    Supplemental Figure 5 shows cellular composition of apheresis material (A) and infused products (B) by IECHS severity.

  • Open Access

    Supplemental Figure 8 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome

    by Hrishikesh K. Srinagesh, Anne Marijn Kramer, John H. Baird, Agnes Reschke, Bita Sahaf, Juancarlos Cancilla, Shriya Syal, Yi-Jiun Su, Neha Agarwal, Alexandria M. Jensen, et al.

    Supplemental Figure 8 shows the individual laboratory and CAR T values for the patient with severe IECHS who underwent daily cytokine profiling.